SCARTOZZI, MARIO
 Distribuzione geografica
Continente #
EU - Europa 184.375
NA - Nord America 17.315
AS - Asia 1.906
SA - Sud America 28
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 16
Totale 203.679
Nazione #
IT - Italia 179.546
US - Stati Uniti d'America 17.205
UA - Ucraina 1.715
CN - Cina 1.409
SE - Svezia 1.132
DE - Germania 717
FI - Finlandia 496
GB - Regno Unito 361
VN - Vietnam 168
SG - Singapore 140
FR - Francia 121
CA - Canada 96
NL - Olanda 74
IN - India 73
BE - Belgio 48
RU - Federazione Russa 41
IE - Irlanda 27
IR - Iran 23
TR - Turchia 22
EU - Europa 18
HK - Hong Kong 17
JP - Giappone 15
AU - Australia 14
BR - Brasile 13
ES - Italia 13
KR - Corea 10
RO - Romania 10
AT - Austria 9
HR - Croazia 9
IS - Islanda 8
MX - Messico 8
PL - Polonia 8
CO - Colombia 7
CH - Svizzera 6
ID - Indonesia 6
JE - Jersey 6
TZ - Tanzania 6
SK - Slovacchia (Repubblica Slovacca) 5
ZA - Sudafrica 5
CL - Cile 4
CZ - Repubblica Ceca 4
GR - Grecia 4
MU - Mauritius 4
TH - Thailandia 4
BG - Bulgaria 3
BZ - Belize 3
IQ - Iraq 3
JO - Giordania 3
MY - Malesia 3
PE - Perù 3
PT - Portogallo 3
TW - Taiwan 3
BY - Bielorussia 2
DK - Danimarca 2
DZ - Algeria 2
EG - Egitto 2
IL - Israele 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SC - Seychelles 2
AF - Afghanistan, Repubblica islamica di 1
AR - Argentina 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
BS - Bahamas 1
HU - Ungheria 1
MO - Macao, regione amministrativa speciale della Cina 1
PA - Panama 1
PH - Filippine 1
TT - Trinidad e Tobago 1
Totale 203.679
Città #
Cagliari 178.509
Fairfield 2.638
Woodbridge 1.936
Chandler 1.562
Houston 1.353
Ashburn 1.254
Seattle 1.023
Wilmington 999
Cambridge 903
Jacksonville 887
Nyköping 837
Ann Arbor 830
Boardman 427
Dearborn 391
Nanjing 313
Helsinki 238
Boston 178
Beijing 169
Dong Ket 166
San Diego 149
New York 139
Shenyang 107
Milan 98
Krefeld 95
Shanghai 92
Nanchang 90
Guangzhou 85
Hebei 85
Rome 83
Verona 82
Toronto 71
Jiaxing 67
Changsha 64
Tianjin 58
Norwalk 51
Bad Bellingen 49
London 48
Pune 48
Mountain View 47
Washington 44
Brussels 43
Orange 41
Redwood City 40
Sassari 37
Jinan 36
Zhengzhou 35
Phoenix 34
Hefei 31
Amsterdam 30
Kunming 25
Ningbo 25
Chicago 22
Redmond 20
Dublin 19
Hangzhou 18
Atlanta 17
Falls Church 17
Saint Petersburg 17
Borås 15
Paris 15
Cedar Knolls 14
Leawood 14
Indiana 13
Taizhou 13
Kilburn 12
Montreal 12
San Francisco 12
Simaxis 12
Edinburgh 11
Hong Kong 11
Hounslow 10
San Mateo 10
West Lafayette 10
Augusta 9
Bari 9
Detroit 9
Islington 9
Los Angeles 9
Vienna 9
Zagreb 9
Chongqing 8
Fuzhou 8
Miami 8
Naples 8
Reykjavik 8
Rio de Janeiro 8
Rockville 8
Singapore 8
Torino 8
Chiswick 7
Naaldwijk 7
New Bedfont 7
Andover 6
Ardabil 6
Dar es Salaam 6
Romainville 6
Santiago de Cali 6
Xian 6
Bologna 5
Boulder 5
Totale 197.158
Nome #
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3.247
null 3.029
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 2.944
Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer 2.903
Systemic therapy for the treatment of endometrial cancer 2.737
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy 2.735
Clustered protocadherins methylation alterations in cancer 2.721
Aspirin and cancer risk 2.698
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? 2.640
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib. Results from a single centre prospective cohort study. 2.537
BRAF-mutant colorectal cancer, a different breed evolving 2.477
Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. 2.316
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.301
Acetylsalicylic acid as a neo-adjuvant agent during preoperative chemoradiation for rectal cancer 2.268
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib: preliminary results from a single prospective cohort study. 2.235
CREAM study: Clinical correlation between ipilimumab-Related colitis And intestinal Microbiote in metastatic melanoma patients 2.209
Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report 2.197
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. Risultati di uno studio prospettico. 2.125
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 2.119
Molecular-biology-driven treatment for metastatic colorectal cancer 2.062
Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? 2.054
HYPOTHYROIDISM AND THYROID AUTOIMMUNITY AS A PROGNOSTIC BIOMARKER OF BETTER RESPONSE IN METASTATIC CANCER LONG SURVIVORS TREATED WITH SUNITINIB 2.030
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 2.028
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 2.002
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. 1.979
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 1.953
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 1.951
The abscopal effect in the era of cancer immunotherapy: a spontaneous synergism boosting anti-tumor immunity? 1.949
Health related quality of life in patients with onco-hematological diseases 1.856
Ipotiroidismo e autoimmunità tiroidea in pazienti affetti da carcinoma renale metastatico trattati con sunitinib con un follow-up di 30 mesi. 1.784
Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: Key role of interleukin-6 1.766
The immune revolution in gastrointestinal tumours: leading the way or just following? 1.753
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 1.750
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 1.708
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study 1.706
Hypothyroidism and thyroid autoimmunity in metastatic renal cell carcinoma patients treated with sunitinib: 2 years follow-up of long survivors from a single centre experience. 1.635
Gold nanoparticles: A new golden Era in oncology? 1.584
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy 1.531
Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer 1.512
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 1.436
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 1.395
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 1.326
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 1.276
New therapeutic targets in pancreatic cancer 1.274
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 1.266
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 1.251
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 1.248
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 1.246
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.234
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 1.217
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 1.203
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 1.193
From central to sentral (Serum angiogenesis central): Circulating predictive biomarkers to anti-VEGFR therapy 1.171
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 1.138
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 1.128
Immunotherapy for colorectal cancer: where are we heading? 1.124
null 1.080
Cancer immunotherapy-associated hypophysitis 1.072
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 1.064
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 1.061
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials 1.051
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 1.033
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 1.031
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group 1.014
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 966
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 965
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 957
Lactate dehydrogenase in hepatocellular carcinoma: something old, something new 912
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 902
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 882
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 866
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 860
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 847
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 826
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 820
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 812
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 807
FOLFOX or CAPOX in stage II to III colon cancer: Efficacy results of the italian three or six colon adjuvant trial 799
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 786
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 780
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 722
Aflibercept, a new way to target angiogenesis in the second line treatment of metastatic colorectal cancer (mCRC) 699
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 689
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 682
Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue 669
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 649
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 647
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort 631
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology 629
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 629
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough 619
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 618
The PANDA study: A randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients 595
Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis 595
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 578
The role of fetal programming in human carcinogenesis - May the Barker hypothesis explain interindividual variability in susceptibility to cancer insurgence and progression? 570
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study 557
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 529
Bone metastases in biliary cancers: A multicenter retrospective survey 525
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial 523
Totale 140.705
Categoria #
all - tutte 294.775
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 294.775


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.855 0 0 0 0 0 0 0 0 0 653 1.053 1.149
2019/202042.900 2.987 1.427 363 1.010 15.269 10.901 5.751 1.529 873 731 799 1.260
2020/202156.110 1.658 2.112 2.076 15.778 10.994 6.963 3.642 3.554 1.399 3.262 2.661 2.011
2021/202217.497 1.352 1.105 469 843 911 960 717 3.198 1.945 1.597 2.150 2.250
2022/202328.923 3.004 3.938 3.127 2.551 2.388 2.988 1.413 2.079 2.114 1.832 2.196 1.293
2023/202426.718 1.263 1.352 1.669 2.055 2.765 4.877 5.026 4.303 2.023 1.385 0 0
Totale 205.077